BridgeMD
New treatment option for Thoracic Paravertebral Block
Official title The Impact of Ultrasound-Guided Superficial and Deep Paravertebral Nerve Blocks at the Superior Costotransverse Ligament on Hemodynamics During the Induction Phase of Thoracoscopic Lung Lobectomy: A Multicenter, Double-Blind, Randomized Controlled Trial
ClinicalTrials.gov ID: NCT06841822
What this study is testing
- What it's testing
- This study aims to determine whether performing a paravertebral nerve block at the superficial surface of the superior costotransverse ligament (SCTL) (without needle penetration of the SCTL) is more effective in maintaining hemodynamic stability during the induction phase of thoracoscopic lung lobectomy compared to the deep surface of the SCTL (with needle penetration of the SCTL). This is a multicenter, double-blind, randomized controlled trial enrolling a total of 168 participants across five hospitals.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients scheduled for elective two-port video-assisted thoracoscopic lobectomy
- Age: ≥18 years
- ASA classification: I-III
- BMI: 18-30 kg/m²
You likely can't join if
- Severe hypertension (SBP ≥180 mmHg or DBP ≥110 mmHg)
- MAP \<70 mmHg before anesthesia induction
- Emergency surgery
- Severe cardiovascular disease, including history of cerebral or thoracic/abdominal aortic aneurysm
- Congestive heart failure (New York Heart Association class III or IV)
- Untreated or unstable ischemic heart disease
See the full eligibility criteria
- Patients scheduled for elective two-port video-assisted thoracoscopic lobectomy
- Age: ≥18 years
- ASA classification: I-III
- BMI: 18-30 kg/m²
- Severe hypertension (SBP ≥180 mmHg or DBP ≥110 mmHg)
- MAP \<70 mmHg before anesthesia induction
- Emergency surgery
- Severe cardiovascular disease, including history of cerebral or thoracic/abdominal aortic aneurysm
- Congestive heart failure (New York Heart Association class III or IV)
- Untreated or unstable ischemic heart disease
- Severe aortic or mitral valve disease
- Pregnancy or lactation
- Coagulation disorders
- Bacteremia, sepsis, or infection at the puncture site
- Allergy to study-related drugs
- Severe liver and kidney dysfunction
- Neurological disorders, spinal disease (deformity or trauma), history of spinal surgery, or abnormal skin sensation in the thoracic or back region
- Existing or anticipated difficult airway management
- Other conditions deemed unsuitable for inclusion by the investigators Forty patients who required CT (3D) imaging technology to observe drug diffusion after the implementation of the two methods were included as...
The study team makes the final eligibility decision.
Where it's taking place
- Nanjing, Jiangsu, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nanjing, Jiangsu, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.